logo
Scientists develop revolutionary method to keep dangerous toxins out of rivers and lakes: 'It holds strong potential'

Scientists develop revolutionary method to keep dangerous toxins out of rivers and lakes: 'It holds strong potential'

Yahoo18 hours ago
Scientists develop revolutionary method to keep dangerous toxins out of rivers and lakes: 'It holds strong potential'
Scientists have created a new water treatment material that can more efficiently purify water for release and extract phosphorus for industrial purposes.
According to research on the revolutionary material, published in Springer Nature, the researchers propose the use of "urchin-like La/Cu-Fe3O4 nanocapsules featuring perpendicular La/Cu nanosheets surrounding an Fe3O4 nanosphere core." The material can efficiently remove phosphorus from wastewater to ensure it's pure enough to be released into rivers and lakes.
Wastewater must be treated before release, and much of that process involves removing phosphorus, which causes green algae growth, and disinfecting microorganisms like total coliform. The new material accomplishes both highly efficiently. And, the retrieved phosphorus is a valuable industrial material used to make fertilizers, cleaning agents, and detergents.
According to TechXplore, the system operates without electricity by using a magnetic field to move the material with precision. This reduces energy consumption by over 99% compared to traditional treatment methods, decreasing energy costs and carbon emissions.
"The key to our research is the rapid recovery of phosphorus from sea urchin structural materials and the implementation of a process that precisely controls particles in water with magnetic fields," said Dr. Youngkyun Jung, first author of the study, per TechXplore.
The treatment can be implemented in water purification plants, sewage treatment plants, and industrial wastewater treatment sites. The treated water can be used in precision agriculture, smart farms, eco-friendly industrial parks, and public water and sewage systems, helping to improve water security.
"It holds strong potential for future expansion into multifunctional water treatment platforms," Jung explained, per TechXplore.
This incredible technology can reduce the cost and time it takes to properly treat water for release or recycling. It could work with emergency purification systems for natural disasters, mobile facilities for underdeveloped countries, and portable water treatment devices. This would make water more accessible and affordable to those in need, reducing water scarcity around the world.
On top of helping people get usable water, the technology also helps the planet. It ensures harmful materials — like the microorganisms in wastewater — don't pollute lakes and rivers. The eco-friendly system will reduce planet-warming emissions created during the treatment process, helping work toward a cleaner, cooler future.
The material has been successfully tested in labs, so the next step is likely further development and eventually pilot projects.
How concerned are you about the plastic waste in our oceans?
Extremely
I'm pretty concerned
A little
Not much
Click your choice to see results and speak your mind.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Patients With Acromegaly Face Higher Cancer Risk
Patients With Acromegaly Face Higher Cancer Risk

Medscape

time10 minutes ago

  • Medscape

Patients With Acromegaly Face Higher Cancer Risk

TOPLINE: Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the general population. These data underscored the urgent need to integrate cancer screening protocols into routine care for patients with acromegaly to facilitate earlier detection and intervention. METHODOLOGY: Excess growth hormone secretion in patients with acromegaly increases the levels of insulin-like growth factor, a known cancer risk factor; however, the true prevalence of cancer in these patients is not well known. Researchers conducted a retrospective cohort analysis using data from a multinational research network platform to compare cancer prevalence in individuals with acromegaly and those without the condition. Patients with acromegaly (n = 10,207; mean age at disease onset, 43.2 years; 52.9% women) were matched with 102,070 individuals from the general population without the condition. TAKEAWAY: Patients with acromegaly had a 3.3-fold increased odds of developing leukemia/lymphoma (95% CI, 2.3-4.67), a 1.9-fold increased odds of developing ovarian cancer (95% CI, 1.3-2.8), a 1.8-fold increased odds of developing breast cancer (95% CI, 1.5-2.0), 1.9-fold increased odds of developing lung cancer (95% CI, 1.5-2.3), and a 1.5-fold increased odds of developing prostate cancer (95% CI, 1.3-1.8). The onset of certain cancers, specifically ovarian, lung, liver, and neuroendocrine, occurred much earlier (3.2-7.2 years) in patients with acromegaly than in control individuals from the general population. IN PRACTICE: 'Our findings suggest that acromegaly may play a bigger role in cancer risk than previously thought, highlighting the need for increased awareness and early cancer screening in this population,' said the lead researcher in a press release. SOURCE: This study was led by Hitam Hagog Natour, MD, Thomas Jefferson University Hospital in Philadelphia. It was presented on July 14, 2025, at the ENDO 2025: The Endocrine Society Annual Meeting in San Francisco. LIMITATIONS: This study did not report any specific limitations. DISCLOSURES: This study did not report any specific funding or conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Defence Tech Startup Ammunic Systems Bags USD 1.1 Mn Funding
Defence Tech Startup Ammunic Systems Bags USD 1.1 Mn Funding

Entrepreneur

time10 minutes ago

  • Entrepreneur

Defence Tech Startup Ammunic Systems Bags USD 1.1 Mn Funding

The funding will be deployed to boost research and development, scale manufacturing, expand the team, and enhance new and existing product lines focused on indigenous defence technology. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Ammunic Systems has raised USD 1.1 million in a seed funding round co-led by India Accelerator and Finvolve. The funding will be deployed to boost research and development, scale manufacturing, expand the team, and enhance new and existing product lines focused on indigenous defence technology. The capital infusion is set to support Ammunic Systems' ambition of accelerating its innovation roadmap and advancing India's self-reliance in strategic defence solutions. With a strong emphasis on cutting-edge technologies, the startup is positioning itself as a key player in modern warfare systems. "This investment from India Accelerator is not just capital; it is a vote of confidence in a mission we have poured our hearts into. At Ammunic Systems, we are not just building defence technologies; we are building belief — that India can lead from the front in securing its own future," said Priyanka Singhal, Founder of Ammunic Systems. Founded in 2024, Ammunic Systems is headquartered in Bengaluru. The company specialises in the research and development of advanced weapon systems. Its core expertise lies in electronic fuzes, warheads, and munition integration technologies. These products aim to offer precision, safety, and efficiency for current and future defence needs. Ammunic Systems provides end-to-end solutions across the defence product cycle — from concept design and testing to full-scale production. The startup aspires to become a leading innovator in the defence and aerospace sector by focusing on indigenous manufacturing and next-generation technologies. The investment community views such ventures as crucial to reducing India's dependency on defence imports. "India is at a critical point in its defence evolution, which makes indigenous technological capabilities national priorities. Ammunic Systems exemplifies the deep-tech innovation needed to strengthen our defence ecosystem," said Ashish Bhatia, Founder of India Accelerator and Co-founder of Finvolve.

5-Grass SLIT Shows Benefit in Allergic Rhinoconjunctivitis
5-Grass SLIT Shows Benefit in Allergic Rhinoconjunctivitis

Medscape

time2 hours ago

  • Medscape

5-Grass SLIT Shows Benefit in Allergic Rhinoconjunctivitis

TOPLINE: Five-grass-pollen liquid sublingual immunotherapy (SLIT) reduced symptoms and the need for medications to treat symptoms in patients with allergic rhinoconjunctivitis (ARC) with or without asthma — while maintaining a favorable safety profile and providing consistent benefits across ages, comorbidities, and treatment durations. METHODOLOGY: Researchers conducted a systematic review and meta-analysis to evaluate the efficacy of five-grass-pollen liquid SLIT in patients with ARC with or without asthma. Nine studies comparing the efficacy of interventional immunotherapy with that of placebo in this population were included. The key outcomes comprised symptom severity, assessed as the symptom score; a reduction in medication use, assessed as the medication score; and the incidence of adverse events (AEs). TAKEAWAY: A pooled analysis of eight studies showed a significant reduction in symptom score in the interventional immunotherapy group vs the placebo group (standardized mean difference [SMD], -0.34; 95% CI, -0.62 to -0.06; P < .05) over a mean follow-up of 19 months. Analysis of data pooled from six studies showed a significant reduction in use of drugs for symptoms in the interventional immunotherapy group vs the placebo group (SMD, -0.54; 95% CI, -0.97 to -0.10; P < .05) over a mean follow-up of 20 months. AEs occurred in 20.6% of participants in the interventional immunotherapy group vs 17.5% in the placebo group (P = .46), with treatment discontinuation rates due to AEs of 3.0% and 1.8%, respectively (P = .41). Treatment efficacy remained consistent regardless of cumulative dose, treatment duration, or asthma status. IN PRACTICE: '[The findings] suggest that the dose of five-grass SLIT-liquid can be safely adjusted for better adverse event management without compromising treatment outcomes,' the authors of the study wrote. 'This flexibility makes it possible to tailor treatment according to the patient's condition while addressing their needs and expectations,' they added. SOURCE: Danilo Di Bona, with the University of Foggia, Foggia, Italy, was the corresponding author of the study, which was published online on July 17 in the Journal of Investigational Allergology and Clinical Immunology. LIMITATIONS: The analysis had a relatively small sample size, variation in dosages and treatment durations across studies, and incomplete reporting of AEs in some studies. DISCLOSURES: This study was funded by Stallergenes Greer, a pharmaceutical company. One author declared receiving fees from this company. Some authors reported receiving consulting fees; payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events; or support for attending meetings or travel and serving on data safety monitoring boards or advisory boards for various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store